Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Completed

Conditions studied: Advanced Solid Tumors, Lymphoma

In brief

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.

Key facts

Study ID

NCT03361358

Run by

Agios Pharmaceuticals, Inc.

People needed

44

Starts

2018-03-01

Expected to finish

2019-09-30

Last updated by the study team

2020-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be ≥18 years of age.
• Have a histologically confirmed diagnosis of an advanced solid tumor (other than a primary CNS malignancy) or lymphoma.
• Have archival tumor tissue that can be provided for assessment of MTAP deletion status.
• Have given written informed consent to participate in this study.

You may not qualify if…

• Have a primary CNS malignancy (eg, GBM).
• Have a medical or psychological condition deemed by the Investigator likely to interfere with the subject's ability to give informed consent or participate in the study.

Where it is running

• Boston, MA — Boston, Massachusetts, United States
• Nashville, TN — Nashville, Tennessee, United States
• Barcelona, Spain — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.